Please check your internet connection and try again.
# Montelukast/Levocetirizine
## Overview
A fixed-dose combination (FDC) of a leukotriene receptor antagonist (montelukast) and a second-generation H1-receptor antagonist (levocetirizine). This combination provides synergistic effects in managing allergic rhinitis and chronic urticaria by addressing both histamine-mediated and leukotriene-mediated pathways.
## Primary Indications
* Allergic Rhinitis (Seasonal and Perennial)
* Chronic Urticaria
* Adjunctive therapy for asthma (where allergic rhinitis is a significant contributor)
## Adult Dosing
* **Standard dose:** One tablet (montelukast 10 mg / levocetirizine 5 mg) administered orally once daily, typically in the evening.
## Pediatric Dosing
* **Children 6–14 years:** Generally not recommended for the 10mg/5mg FDC. Use age-appropriate formulations (e.g., chewable montelukast 5 mg and levocetirizine 2.5 mg) administered separately according to pediatric weight-based/age guidelines.
* *Note: Dosing depends on specific regional regulatory approval and local pediatric protocols; always verify labeling for the specific product.*
## Dose Adjustments
* **Renal Impairment:** Reduce levocetirizine dose based on creatinine clearance (CrCl). If CrCl < 50 mL/min, the combination product is generally contraindicated due to the fixed dose.
* **Hepatic Impairment:** No specific montelukast adjustment, but caution is advised in severe cases.
## Contraindications
* Hypersensitivity to montelukast, levocetirizine, cetirizine, or any component of the formulation.
* End-stage renal disease (CrCl < 10 mL/min) or patients undergoing hemodialysis (due to levocetirizine component).
## Adverse Effects
* **Common:** Somnolence, fatigue, nasopharyngitis, dry mouth.
* **Serious (Montelukast-related):** Neuropsychiatric events including agitation, aggression, depression, sleep disturbances, suicidal ideation, and tremor.
* **General:** Potential for elevated liver enzymes.
## Key Drug Interactions
* **CNS Depressants:** Risk of additive sedation if combined with alcohol or other sedatives due to levocetirizine.
* **CYP450 Inducers:** Phenobarbital, phenytoin, and rifampin may decrease montelukast plasma concentrations.
* **Theophylline:** Potential for modest increases in theophylline levels.
## Monitoring
* **Neuropsychiatric:** Monitor for mood or behavior changes (Black Box/Warning for montelukast).
* **Renal Function:** Routine monitoring in patients with underlying renal impairment.
* **Sedation:** Assess for excessive somnolence, especially when driving or operating machinery.
## Clinical Pearls
* **Timing:** Administering in the evening maximizes relief for morning nasal symptoms and accounts for the sedative effects of levocetirizine.
* **Neuropsychiatric Risk:** Discuss the FDA "Boxed Warning" regarding neuropsychiatric events with patients/caregivers; discontinue immediately if behavioral changes occur.
* **Not for Acute Asthma:** Emphasize that neither component acts as a rescue medication for acute bronchospasm.
* **Availability:** In many jurisdictions, this combination is available as a single pill; if unavailable, clinicians often prescribe the two agents as individual tablets.
***
**Educational Disclaimer:** This information is for educational purposes only. Drug dosing, contraindications, and availability can change. Always consult the most recent FDA-approved prescribing information, the product's official package insert, or a reliable clinical decision support database (e.g., Lexicomp, UpToDate) before prescribing or administering medication.
